<DOC>
	<DOCNO>NCT00050440</DOCNO>
	<brief_summary>The purpose test safety effectiveness investigational chemotherapy agent patient persistent recurrent endometrial cancer .</brief_summary>
	<brief_title>Phase 2 Study ET-743 ( Trabectedin ) Patients With Persistent Recurrent Endometrial Carcinoma</brief_title>
	<detailed_description>Patients enrol study study-specific entry criterion meet informed consent obtain . Patients required attend regular clinic visit receive study medication status monitor . They also require radiologic tumor assessment perform multiple time throughout study . A detailed explanation provide Investigator conduct study . Trabectedin 1.3 mg/m2 give every 21 day patient intravenously ( i.v ) . 3-hour period via central venous catheter ( refer `` central line '' ) tube ( ie , catheter ) place large vein use administer medication . Dexamethasone 4 mg give orally ( p.o . ) day trabectedin dexamethasone 20 mg give i.v . 30 minute trabectedin . Dexamethasone 4 mg p.o . give 2 day follow trabectedin administration .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Diagnosis advance metastatic endometrial carcinoma Progressive disease 1 cytotoxic chemotherapy regimen give advanced/metastatic disease At least one measureable tumor lesion Adequate bone marrow , hepatic renal function Performance status ECOG 0 1 Prior exposure trabectedin Known hypersensitivity dexamethasone component trabectedin Less 4 week since last radiation therapy since last dose hormonal therapy , biological therapy , therapy investigational agent , chemotherapy History another neoplastic disease unless remission 5 year Known metastasis ( spread ) cancer central nervous system serious illness specify protocol Current pregnancy , lactation , childbearing potential without adequate method contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Endometrial</keyword>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Ecteinascidin 743</keyword>
	<keyword>ET743</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Alkylating Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>